MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
48.19
+0.14 (0.29%)
Oct 29, 2024, 4:00 PM EDT - Market closed

MLTX Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
26.0522.3223.0121.66
Research & Development
52.3631.842.0512.64
Operating Expenses
78.454.1265.0634.29
Operating Income
-78.4-54.12-65.06-34.29
Currency Exchange Gain (Loss)
-0.230.150.33-0.07
Other Non Operating Income (Expenses)
20.619.990.27-0
EBT Excluding Unusual Items
-58.02-43.98-64.47-34.37
Other Unusual Items
----30
Pretax Income
-58.02-43.98-64.47-64.37
Income Tax Expense
0.220.090.040.01
Earnings From Continuing Operations
-58.24-44.08-64.51-64.37
Minority Interest in Earnings
3.448.0714.53-
Net Income
-54.8-36.01-49.97-64.37
Net Income to Common
-54.8-36.01-49.97-64.37
Shares Outstanding (Basic)
6049298
Shares Outstanding (Diluted)
6049298
Shares Change (YoY)
49.62%67.30%274.47%-
EPS (Basic)
-0.92-0.73-1.70-8.21
EPS (Diluted)
-0.92-0.73-1.70-8.21
Free Cash Flow
-64.93-43.06-55.91-42.27
Free Cash Flow Per Share
-1.09-0.88-1.90-5.39
EBITDA
-78.35-54.11-65.05-34.29
D&A For EBITDA
0.060.010.010.01
EBIT
-78.4-54.12-65.06-34.29
Source: S&P Capital IQ. Standard template. Financial Sources.